Hanyang Bio-Tech to be listed on Emerging Stock Board on 5/20, focusing on ADC drug field
Hanyang Bio-Tech will be listed on the Emerging Stock Board on May 20, focusing on ADC (Antibody-Drug Conjugate) new drug technology platform development. General Manager Lin Yang-Sheng stated that substantial negotiations are underway with several domestic and international biotech and pharmaceutical companies for technology platform applications, and specific licensing results are hoped for in the near future.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 21:44
- 🔍 Collected: May 12, 2026 at 22:02 (17 min after Published)
- 🤖 AI Analyzed: May 13, 2026 at 03:54 (5h 52m after Collected)
Central News Agency
(Central News Agency reporter He Hsiu-Ling, Taipei 12th) Hanyang Bio-Tech is scheduled to be listed on the Emerging Stock Board on May 20, mainly focusing on the development of ADC (Antibody-Drug Conjugate) new drug technology platforms. Hanyang Bio-Tech General Manager Lin Yang-Sheng stated that substantial negotiations have been initiated with several domestic and international biotech and pharmaceutical companies regarding the application of its technology platform. The technology licensing business continues to advance this year, with hopes for concrete licensing results in the near future.
He pointed out that ADC drugs have become one of the most promising emerging therapies in global precision oncology treatment in recent years. The design principle of ADC is to connect a monoclonal antibody with high tumor selectivity to a cytotoxic drug or immunostimulant payload through a linker, allowing the drug to be precisely delivered to tumor cells, thereby achieving the ideal goal of improving efficacy and reducing toxicity.
He said that Hanyang Bio-Tech, with its independently developed global universal hydrophilic linker technology and hydrophilic payload modification technology as its core, adopts a technology licensing model to connect with international biotech and pharmaceutical manufacturers. (Editor: Pan Yi-Ching) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to grasp the latest news instantly.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.
(Central News Agency reporter He Hsiu-Ling, Taipei 12th) Hanyang Bio-Tech is scheduled to be listed on the Emerging Stock Board on May 20, mainly focusing on the development of ADC (Antibody-Drug Conjugate) new drug technology platforms. Hanyang Bio-Tech General Manager Lin Yang-Sheng stated that substantial negotiations have been initiated with several domestic and international biotech and pharmaceutical companies regarding the application of its technology platform. The technology licensing business continues to advance this year, with hopes for concrete licensing results in the near future.
He pointed out that ADC drugs have become one of the most promising emerging therapies in global precision oncology treatment in recent years. The design principle of ADC is to connect a monoclonal antibody with high tumor selectivity to a cytotoxic drug or immunostimulant payload through a linker, allowing the drug to be precisely delivered to tumor cells, thereby achieving the ideal goal of improving efficacy and reducing toxicity.
He said that Hanyang Bio-Tech, with its independently developed global universal hydrophilic linker technology and hydrophilic payload modification technology as its core, adopts a technology licensing model to connect with international biotech and pharmaceutical manufacturers. (Editor: Pan Yi-Ching) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download the Central News Agency 'First-hand News' APP to grasp the latest news instantly.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.